MiMARK
Mimark Diagnostics is a women‑founded biotechnology spin‑off (founded 2021) from a Barcelona research institute that develops protein‑based diagnostics using minimally invasive gynecological fluid samples. The company translates mass‑spectrometry discovery into validated immunoassays intended for clinical use (endometrial cancer and endometriosis), conducts multicenter clinical validation, and pursues scale‑up and regulatory protection for in vitro diagnostic deployment.
Industries
Nr. of Employees
small (1-50)
Patents
Products
IVD immunoassay for endometrial cancer detection (uterine fluid‑based)
An objective protein‑based immunoassay panel measured in uterine fluid obtained from pipelle biopsies to aid detection of endometrial cancer in post‑menopausal patients with abnormal uterine bleeding.
Immunoassay for endometriosis detection (cervical fluid‑based)
A protein‑based immunoassay using minimally invasive cervical cytology samples (cervical swabs) to enable earlier detection of endometriosis; proof‑of‑concept data reported in ~200 cervical swabs.
GyLDEC
GyLDEC is an IVD Immunoassay to aid in the detection of Endometrial cancer, measured in uterine fluids obtained from pipelle biopsies.
GyLDEndo
A minimally invasive protein-based immunoassay designed for earlier detection of endometriosis using cervical cytology samples, providing results within 48 hours.
GyLDa
Gynecological Liquid Diagnostics platform that harnesses the diagnostic power of gynecological fluid.
IVD immunoassay for endometrial cancer detection (uterine fluid‑based)
An objective protein‑based immunoassay panel measured in uterine fluid obtained from pipelle biopsies to aid detection of endometrial cancer in post‑menopausal patients with abnormal uterine bleeding.
Immunoassay for endometriosis detection (cervical fluid‑based)
A protein‑based immunoassay using minimally invasive cervical cytology samples (cervical swabs) to enable earlier detection of endometriosis; proof‑of‑concept data reported in ~200 cervical swabs.
GyLDEC
GyLDEC is an IVD Immunoassay to aid in the detection of Endometrial cancer, measured in uterine fluids obtained from pipelle biopsies.
GyLDEndo
A minimally invasive protein-based immunoassay designed for earlier detection of endometriosis using cervical cytology samples, providing results within 48 hours.
GyLDa
Gynecological Liquid Diagnostics platform that harnesses the diagnostic power of gynecological fluid.
Services
Collaborative development, clinical validation support and licensing/partnership for assay integration into existing IVD platforms and clinical workflows.
Collaborative development, clinical validation support and licensing/partnership for assay integration into existing IVD platforms and clinical workflows.
Expertise Areas
- Biomarker discovery and verification
- Proteomics and targeted mass spectrometry
- Immunoassay design and analytical validation
- Clinical validation and multicenter clinical studies
Key Technologies
- Mass spectrometry (discovery proteomics)
- Targeted proteomics (LC‑PRM)
- Protein‑based immunoassays
- Antibody and reagent development
News & Updates
Recognition as TOP1 in the IV edition of the EAE Business School rankings for women entrepreneurs in Catalonia.
Participation in a mentorship program for grantees of the European Innovation Council Accelerator.
Press article reporting on company fundraising efforts to enter the market.
Report highlighting the women's health market referenced by the company.
Project funded under the EIC Accelerator program (WomEC).
Authorship or contribution to multiple peer‑reviewed publications on proteomic biomarkers and diagnostic workflows for endometrial cancer.
Recognition as TOP1 in the IV edition of the EAE Business School rankings for women entrepreneurs in Catalonia.
Participation in a mentorship program for grantees of the European Innovation Council Accelerator.
Press article reporting on company fundraising efforts to enter the market.
Report highlighting the women's health market referenced by the company.
Project funded under the EIC Accelerator program (WomEC).
Authorship or contribution to multiple peer‑reviewed publications on proteomic biomarkers and diagnostic workflows for endometrial cancer.